MHRA-100305-PIP01-21

Key Facts

Active Substance
Active Substance:
  • Single chain urokinase plasminogen activator (scuPA)
Invented Name
Not yet available
PIP Number MHRA-100305-PIP01-21
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Powder for solution for injection
Therapeutic area
Therapeutic area:
  • Pneumology - Allergology
Conditions / Indications
Conditions / Indications:
  • Treatment of pleural effusion
Route(s) of administration
Route(s) of administration:
  • Intrapleural use
PIP applicant
  • Lung Therapeutics, Inc
  • Country United States
  • Tel +17378021989
  • Email info@lungtx.com
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Single chain urokinase plasminogen activator (scuPA).pdf
Published Date 29/07/2022